Compare Byrna Technologies Inc (BYRN) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Byrna Technologies Inc vs Illumina, Inc. — how do they compare? Byrna Technologies Inc trades at $4.32 (market cap $106.74M), while Illumina, Inc. trades at $190.95 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 272.8× Byrna Technologies Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Byrna Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BYRN | ILMN | |
|---|---|---|
Market Cap | $106.74M | $29.12B |
Sector | Technology | Health |
52-Week High | $27.63 | $205.10 |
52-Week Low | $3.18 | $91.00 |
Enterprise Value | $98.35M | $30.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BYRN trades at $4.34, down 10.52% in 24 hours, with a mixed technical outlook showing bullish moving averages but neutral oscillators. The company reported a net loss in 2026 with a negative net income margin of -3.39%, though it maintains a strong gross profit margin of 52.51%. Recent leadership appointments aim to bolster marketing and retail expansion, while Q2 2026 earnings missed estimates with a loss of $0.44 per share.
The outlook is challenged by recent earnings misses and declining revenue, but analyst consensus remains bullish with 71% buy ratings. Key risks include execution in sales turnaround and competitive pressures. Upside depends on successful implementation of new growth initiatives and improved financial performance in upcoming quarters.
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Byrna Technologies Inc
Byrna Technologies specializes in less-lethal personal security devices. It develops and manufactures innovative handheld launchers and projectiles designed for self-defense, law enforcement, and private security use.
Read more on BYRN →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
